Compositions and methods for treatment of hyperplastic disorders
AssigneeThe University of Toledo
InventorsSteven H. Selman, Channing L. Hinman
Life of this patent
Estimating the term…
Abstract
A method for treating a subject includes injecting a therapeutic amount of a composition derived from a cobra toxin into a tissue of the subject in an amount sufficient to diminish at least one symptom of a hyperplastic disorder.
Claims14
A method to treat a subject having a non-cancerous hyperplastic prostate disorder, comprising administering to the subject a therapeutically effective amount of an isolated, synthetic or recombinant peptide composition, wherein the peptide composition comprises at least one of the sequences represented by SEQ ID NOS:
- 1-18, or derivatives thereof, wherein the non-cancerous hyperplastic disorder is alleviated.
A method for treating prostatic hyperplasia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a cyclic peptide, 14 amino acids in length with a disulfide bond between residues 3 and 14 (Cys 3 and Cys 14) which consists of the following sequence:
- Leu-Lys-Cys-4-Lys-Leu-7-Pro-Leu-10-Tyr-Lys-Thr-Cys, where 4 is Asn or Gln;
- 7 is Val or Ile;
- 10 is Phe or Ala having one or more of the SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
A method for treating prostatic hyperplasia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a cyclic peptide, 14 amino acids in length with a disulfide bond between residues 3 and 14 (Cys 3 and Cys 14) which consists of the following sequence:
- Leu-Lys-Cys-4-Lys-Leu-7-Pro-Leu-10-Tyr-Lys-Thr-Cys, where 4 is Asn or Gln;
- 7 is Val or Ile;
- 10 is Phe or Ala, having the SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:12, in which at least one amino acid is replaced with its corresponding D-amino acid.
A method for treating a subject with a prostatic disorder, the method comprising:
- injecting a therapeutic amount of a composition derived from a cobra toxin thereof into a prostate gland of the subject patient, thereby alleviating a symptom of prostatic hyperplasia, benign prostatic hyperplasia or prostatic enlargement, wherein the composition comprises one or more peptides having a sequence as shown in SEQ ID NOs:1-18.
A system for treating benign prostate hyperplasia (BPH) of a prostate, comprising:
- administering at least one composition comprising one or more amino acids described in SEQ ID NOs:1-18 near a BPH tissue site of a subject in an amount sufficient to produce necrosis of cells of the BPH tissue site but insufficient to create damage to a majority of the BPH tissue site.
A method for treating prostatic hyperplasia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a cyclic peptide, 14 amino acids in length with a disulfide bond between residues 1 and 12 (Cys 1 and Cys 12) which consists of the following sequence:
- Cys-Thr-Lys-Tyr-5-Leu-Pro-8-Leu-Lys-11-Cys-Lys-Leu, where 5 is Phe or Ala;
- 8 is Val or Ile;
- 11 is Asn or Gln having one or more of the SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
A method for treating prostatic hyperplasia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a peptide, 14 amino acids in length having SEQ ID NO:11.
A method for treating prostatic hyperplasia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a peptide, 14 amino acids in length having SEQ ID NO:12.
Dependencies are inferred from the claim text.